Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats

Pipe-Martin, Hannah; Fletcher, J. M.; Gilor, Chen; Mitchell, Mark A.

doi:10.1016/j.domaniend.2017.09.002

Cited by 5 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypothetically, using an insulin that is most similar in sequence Table 3. Pharmacodynamics (PD) and pharmacokinetics (PK) of short-acting insulin solutions in dogs and cats (Matsuo et al 2003, DeClue et al 2008, Pipe-Martin et al 2018 and least immunogenic is a logical choice; however, the clinical importance of this is questionable. Canine insulin is 100% homologous to porcine insulin and differs from human insulin by only one amino acid.…”

Section: Species Source: Similarities Differences and Clinical Import...mentioning

confidence: 99%

One hundred years of insulin: Is it time for smart?

Gilor

Fleeman

2022

J of Small Animal Practice

Self Cite

View full text Add to dashboard Cite

Smarter understanding of diabetes pathophysiology and pharmacology of insulin therapy can lead to better clinical outcomes. Rather than looking for an insulin formulation that is considered “best” for a general population, it could be appropriate to seek the “smart” insulin choice, tailored to the specific clinical situation. Different treatment goals should be considered, with pros and cons to each. Ideally, insulin therapy in most diabetic dogs should mimic a “basal‐bolus” pattern. The “intermediate”‐acting insulin formulations might provide better “bolus” treatment in dogs than the rapid‐acting formulations used in people. In patients with some residual beta cell function such as many diabetic cats, administering only a “basal” insulin might lead to complete normalisation of blood glucose concentrations. Insulin suspensions (neutral protamine Hagedorn, neutral protamine Hagedorn/regular mixes, lente and protamine zinc insulin) as well as insulin glargine U100 and detemir are “intermediate”‐acting formulations that are administered twice daily. For a formulation to be an effective and safe “basal” insulin, its action should be roughly the same every hour of the day. Currently, only insulin glargine U300 and insulin degludec meet this standard in dogs, whereas in cats, insulin glargine U300 is the closest option.

show abstract

Section: Species Source: Similarities Differences and Clinical Import...mentioning

confidence: 99%